CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.59) by 13.56 percent. This is a 10.87 percent decrease over losses of $(0.46) per share from the same period last year. The company reported quarterly sales of $2.322 million which beat the analyst consensus estimate of $1.641 million by 41.49 percent. This is a 409.21 percent increase over sales of $456.000 thousand the same period last year.